These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 22273510)

  • 1. The in vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia.
    Shenkman B; Livnat T; Misgav M; Budnik I; Einav Y; Martinowitz U
    Platelets; 2012; 23(8):604-10. PubMed ID: 22273510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin- activatable fibrinolysis inhibitor.
    Shenkman B; Einav Y; Livnat T; Budnik I; Martinowitz U
    Int J Lab Hematol; 2015 Aug; 37(4):521-9. PubMed ID: 25651468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor.
    Shenkman B; Einav Y; Livnat T; Budnik I; Martinowitz U
    Blood Transfus; 2014 Jan; 12(1):78-84. PubMed ID: 24333083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.
    Jámbor C; Reul V; Schnider TW; Degiacomi P; Metzner H; Korte WC
    Anesth Analg; 2009 Oct; 109(4):1023-8. PubMed ID: 19762725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM).
    Theusinger OM; Baulig W; Asmis LM; Seifert B; Spahn DR
    Thromb Haemost; 2010 Aug; 104(2):385-91. PubMed ID: 20431856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen and FXIII dose response effects on albumin-induced coagulopathy.
    Hanna J; Winstedt D; Schött U
    Scand J Clin Lab Invest; 2013 Oct; 73(7):553-62. PubMed ID: 24004348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study.
    Dubut J; Goin V; Derray C; Huguenin Y; Fiore M
    J Thromb Haemost; 2024 Sep; 22(9):2589-2600. PubMed ID: 38880178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII.
    Nielsen VG; Kirklin JK
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):793-800. PubMed ID: 19002046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
    Nielsen VG; Steenwyk BL; Gurley WQ
    J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution.
    Haas T; Fries D; Velik-Salchner C; Reif C; Klingler A; Innerhofer P
    Anesth Analg; 2008 May; 106(5):1360-5, table of contents. PubMed ID: 18420845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Tranexamic Acid on Coagulation and Fibrin Clot Properties in Children Undergoing Craniofacial Surgery.
    Fenger-Eriksen C; Lindholm AD; Krogh L; Hell T; Berger M; Hermann M; Fries D; Juul N; Rasmussen M; Hvas AM
    Thromb Haemost; 2020 Mar; 120(3):392-399. PubMed ID: 32016928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood.
    Dirkmann D; Görlinger K; Gisbertz C; Dusse F; Peters J
    Anesth Analg; 2012 Jun; 114(6):1182-8. PubMed ID: 22104068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of plasma factor XIII to thrombin-receptor activated human platelets.
    Nagy B; Simon Z; Bagoly Z; Muszbek L; Kappelmayer J
    Thromb Haemost; 2009 Jul; 102(1):83-9. PubMed ID: 19572072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
    He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
    Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro.
    Schlimp CJ; Cadamuro J; Solomon C; Redl H; Schöchl H
    Blood Transfus; 2013 Oct; 11(4):510-7. PubMed ID: 23245725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury.
    Zentai C; van der Meijden PE; Braunschweig T; Hueck N; Honickel M; Spronk HM; Rossaint R; Grottke O
    Anesth Analg; 2016 Jul; 123(1):38-48. PubMed ID: 27192476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of coagulopathy in thrombocytopenia and Glanzmann thrombasthenia models by fibrinogen and factor XIII as assessed by thromboelastometry.
    Budnik I; Shenkman B; Morozova O; Andreichyn J; Einav Y
    Pathophysiology; 2018 Dec; 25(4):347-351. PubMed ID: 29805054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Ex Vivo Factor XIII Supplementation on Clot Formation in Blood Samples From Cardiac and Scoliosis Surgery Patients.
    Shams Hakimi C; Carling MS; Hansson EC; Brisby H; Hesse C; Radulovic V; Jeppsson A
    Clin Appl Thromb Hemost; 2018 May; 24(4):677-683. PubMed ID: 28651441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.